Cogent Biosciences Presents Preclinical Data Showing Potential Precision of New Cancer Drug

Cogent Biosciences (NASDAQ:COGT) presented early-stage preclinical data showing its experimental drug CGT1145 is over 100 times more selective for a specific gene mutation linked to rare blood cancers compared to existing treatments. The results suggest the potential for fewer side effects and deeper therapeutic impact, with plans to file an Investigational New Drug application later this year.

By Abdul Rahman Mon, June 22, 2026 at 5:14 PM GMT+3 2 min read · Yahoo Finance · June 22, 2026, 14:14 UTC

Tickers: $COGT

Topics: cancer drug JAK2 inhibitor preclinical data

Read the full article at Yahoo Finance

More Health news

Data Suggests United States May Lose Measles Elimination Status The Verge · November 11, 2026, 19:48 UTC
Rising U.S. Measles Outbreaks Pose Significant Economic Burden CNBC · November 11, 2026, 12:00 UTC
FDA Issues Not Approvable Letter for NovoCure's Optune Mya Motley Fool · November 10, 2026, 18:50 UTC
Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data Motley Fool · November 10, 2026, 01:43 UTC
Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug Motley Fool · November 8, 2026, 15:15 UTC
Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026 Motley Fool · November 5, 2026, 01:48 UTC
Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine Motley Fool · November 3, 2026, 20:52 UTC
Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment Motley Fool · November 2, 2026, 17:25 UTC
American Association for Physician Leadership Releases New Book on Systems Thinking and Strategic Change PR Newswire · October 30, 2026, 12:51 UTC
Pennsylvania Reports Nearly 1,400 Measles Cases and Five Deaths Seeking Alpha · October 29, 2026, 16:18 UTC